dQ&A's latest diabetes research includes two presentations from our team at ATTD 2026, one of the world's leading stages for diabetes advancements.
Our research with the ADA shows that people with diabetes are much worse off under the COVID-19 pandemic, compared to the nation as a whole.
Part 2 of dQ&A’s CGM series digs into adoption barriers and the Ambulatory Glucose Profile, which can help people make sense of the data CGMs provide.
We asked patients about using—and endocrinologists about prescribing—a connected insulin pen.
Concerns about family or friends getting COVID-19 and about getting COVID-19 oneself increased, as case numbers rose nationally over the summer.
Our fifth COVID-19 impact survey shows Black & Latino adults with diabetes faced more COVID-19 cases, insulin rationing, and financial strain.
Our research with the ADA reveals severe economic impacts of COVID-19 on Americans with diabetes, including high unemployment and care rationing.
Our fourth COVID-19 survey of U.S. diabetes patients highlights persistent concerns, economic stress, and changing behaviors despite easing lockdowns.
dQ&A reveals how Walmart’s CareZone deal, low mail-order NPS scores, and a pandemic push toward home delivery are reshaping pharmacy apps for diabetes.
